142 related articles for article (PubMed ID: 26904385)
1. A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.
Jonsson F; Ou Y; Claret L; Siegel D; Jagannath S; Vij R; Badros A; Aggarwal S; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2015 Dec; 4(12):711-9. PubMed ID: 26904385
[TBL] [Abstract][Full Text] [Related]
2. Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients.
Cheng Y; Hong K; Chen N; Yu X; Peluso T; Zhou S; Li Y
EJHaem; 2022 Aug; 3(3):815-827. PubMed ID: 36051011
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
4. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
[TBL] [Abstract][Full Text] [Related]
8. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Shah JJ
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
[TBL] [Abstract][Full Text] [Related]
9. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe T; Tobinai K; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Kashihara T; Iida S
Br J Haematol; 2016 Mar; 172(5):745-56. PubMed ID: 26732066
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart AK
Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
[TBL] [Abstract][Full Text] [Related]
12. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-associated tumor lysis syndrome.
Shely RN; Ratliff PD
Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P
Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
[TBL] [Abstract][Full Text] [Related]
17. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Wang M; Cheng J
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():24-30. PubMed ID: 25184233
[TBL] [Abstract][Full Text] [Related]
18. Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients.
Claret L; Mercier F; Houk BE; Milligan PA; Bruno R
Cancer Chemother Pharmacol; 2015 Sep; 76(3):567-73. PubMed ID: 26198314
[TBL] [Abstract][Full Text] [Related]
19. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
[TBL] [Abstract][Full Text] [Related]
20. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
Claret L; Girard P; Hoff PM; Van Cutsem E; Zuideveld KP; Jorga K; Fagerberg J; Bruno R
J Clin Oncol; 2009 Sep; 27(25):4103-8. PubMed ID: 19636014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]